4.4 Article

Study of the Response Regulator Rrp1 Reveals Its Regulatory Role in Chitobiose Utilization and Virulence of Borrelia burgdorferi

期刊

INFECTION AND IMMUNITY
卷 81, 期 5, 页码 1775-1787

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/IAI.00050-13

关键词

-

资金

  1. [AI073354]
  2. [AI078958]

向作者/读者索取更多资源

Life cycle alternation between arthropod and mammals forces the Lyme disease spirochete, Borrelia burgdorferi, to adapt to different host milieus by utilizing diverse carbohydrates. Glycerol and chitobiose are abundantly present in the Ixodes tick. B. burgdorferi can utilize glycerol as a carbohydrate source for glycolysis and chitobiose to produce N-acetylglucosamine (GlcNAc), a key component of the bacterial cell wall. A recent study reported that Rrp1, a response regulator that synthesizes cyclic diguanylate (c-di-GMP), governs glycerol utilization in B. burgdorferi. In this report, we found that the rrp1 mutant had growth defects and formed membrane blebs that led to cell lysis when GlcNAc was replaced by chitobiose in the growth medium. The gene chbC encodes a key chitobiose transporter of B. burgdorferi. We found that the expression level of chbC was significantly repressed in the mutant and that constitutive expression of chbC in the mutant successfully rescued the growth defect, indicating a regulatory role of Rrp1 in chitobiose uptake. Immunoblotting and transcriptional studies revealed that Rrp1 is required for the activation of bosR and rpoS and that its impact on chbC is most likely mediated by the BosR-RpoS regulatory pathway. Tick-mouse infection studies showed that although the rrp1 mutant failed to establish infection in mice via tick bite, exogenous supplementation of GlcNAc into unfed ticks partially rescued the infection. The finding reported here provides us with new insight into the regulatory role of Rrp1 in carbohydrate utilization and virulence of B. burgdorferi.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

Single bioengineered ncRNA molecule for dual-targeting toward the control of non-small cell lung cancer patient-derived xenograft tumor growth

Hannah Petrek, Pui Yan Ho, Neelu Batra, Mei-Juan Tu, Qianyu Zhang, Jing-Xin Qiu, Ai-Ming Yu

Summary: This study introduces a novel technology for dual-targeting of two miRNAs in NSCLC cells, showing greater efficacy in inhibiting cell growth and colony formation compared to using individual miRNAs alone. Additionally, a specific miRNA-loaded nanomedicine demonstrated the best effectiveness in controlling tumor growth in NSCLC patient-derived xenograft mouse models.

BIOCHEMICAL PHARMACOLOGY (2021)

Review Pharmacology & Pharmacy

Multifaceted Factors Causing Conflicting Outcomes in Herb-Drug Interactions

Young Hee Choi, Young-Won Chin

Summary: Studies have shown that metabolic enzyme and/or transporter-mediated pharmacokinetic changes in a drug caused by concomitant herbal products may affect efficacy and toxicity, but discrepancies between predictive data and clinical significance still exist, adding to confusion regarding the use of herbal products and drug combinations.

PHARMACEUTICS (2021)

Article Plant Sciences

Sesquiterpenoids from the Aerial Parts of Salvia plebeia with Inhibitory Activities on Proprotein Convertase Subtilisin/Kexin Type 9 Expression

Piseth Nhoek, Hee-Sung Chae, Young-Mi Kim, Pisey Pel, Jungmoo Huh, Hyun Woo Kim, Young Hee Choi, Kyeong Lee, Young-Won Chin

Summary: A phytochemical investigation of the methanol extract of Salvia plebeia led to the identification of 19 compounds, including new norsesquiterpene and eudesmane sesquiterpenoids. While most compounds did not inhibit the PCSK9-LDLR interactions, compounds 1, 9, and 10 were found to downregulate PCSK9 mRNA expression.

JOURNAL OF NATURAL PRODUCTS (2021)

Article Pharmacology & Pharmacy

A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergisms

Young Hee Choi, Chao Zhang, Zhenzhen Liu, Mei-Juan Tu, Ai-Xi Yu, Ai-Ming Yu

Summary: This study developed a novel pharmacokinetic (PK)-pharmacodynamic (PD) model for assessing combination treatment by considering contributions from individual drugs, and incorporated the combination index method to define in vivo synergism accurately. The research found that sorafenib contributed more to tumor growth inhibition compared to coadministered doxorubicin, explaining previously inexplicable clinical observations. This model and strategy will have broad applications in translational research for identifying optimal dosage combinations with stronger synergy to improve therapeutic outcomes.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2021)

Article Oncology

The Cationic Amphiphilic Drug Hexamethylene Amiloride Eradicates Bulk Breast Cancer Cells and Therapy-Resistant Subpopulations with Similar Efficiencies

Anastasia L. Berg, Ashley Rowson-Hodel, Michelle Hu, Michael Keeling, Hao Wu, Kacey VanderVorst, Jenny J. Chen, Jason Hatakeyama, Joseph Jilek, Courtney A. Dreyer, Madelyn R. Wheeler, Ai-Ming Yu, Yuanpei Li, Kermit L. Carraway

Summary: Preventing drug resistance in cancer stem cells is crucial for improving treatment outcomes in cancer patients. This study found that cationic amphiphilic drugs can effectively target therapy-resistant cancer stem cell populations by inducing cell death through a different mechanism. This discovery has the potential to improve treatment outcomes for breast cancer patients and reduce the risk of tumor recurrence and metastasis.

CANCERS (2022)

Article Biochemistry & Molecular Biology

Phosphoproteomics Unravel HBV Triggered Rewiring of Host Phosphosignaling Events

ZiJie Lim, Nur Khairiah Binte Mohd-Ismail, Evelyn Png, Ching Wooen Sze, Qifeng Lin, Wanjin Hong, Seng Gee Lim, Yee-Joo Tan, Jayantha Gunaratne

Summary: This study investigated the molecular signaling events during early phases of HBV infection by profiling the phosphoproteome of infected cells. The results showed that HBV infection significantly altered the host phosphoproteome and its associated proteins, including kinases. Computational analysis revealed dysregulation of immune response, cell cycle, and RNA processing pathways during HBV infection. Inhibition of CLKs was found to reduce HBV infection. These findings provide potential targets for developing novel therapeutic strategies for HBV treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Pharmacology & Pharmacy

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

Gavin M. Traber, Ai-Ming Yu

Summary: RNA interference (RNAi) is a versatile method for regulating gene expression. Endogenous microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs) form RNA-induced silencing complexes to achieve gene regulation. RNAi-based drugs have been approved for clinical use and advancements in technology aim to improve their efficacy and safety. Chemical modifications and delivery platforms are being explored to enhance the structure, stability, and activity of RNA molecules. Novel biologic RNAi agents are also being developed for research purposes.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)

Article Oncology

Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment

Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao

Summary: Next-generation antiandrogen drugs improve survival and quality of life in advanced prostate cancer patients, but resistance to these drugs is not well understood. This study found that the Wnt5a/FZD2 signaling pathway plays a critical role in promoting enzalutamide resistance, and targeting this pathway could be a potential therapy for advanced prostate cancer.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Biochemistry & Molecular Biology

Suppression of Tumor Growth and Cell Migration by Indole-Based Benzenesulfonamides and Their Synergistic Effects in Combination with Doxorubicin

Phuong Linh Nguyen, Ahmed Elkamhawy, Young Hee Choi, Chang Hoon Lee, Kyeong Lee, Jungsook Cho

Summary: The study evaluated the antitumor effects of a series of CA inhibitors on various cancer cell lines, identifying two compounds with potent anticancer activity against breast cancer cells MCF-7 and SK-BR-3, especially in combination with DOX, demonstrating synergistic cytotoxic effects.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Pharmacology & Pharmacy

50th Anniversary Celebration Collection Special Section on Perspective on Drug Metabolism and Disposition, Part I-Minireview Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research

Joseph M. Cronin, Ai -Ming Yu

Summary: The development of medications requires a thorough understanding of their pharmacokinetic and pharmacodynamic properties. The study of ADME gene products and their functions has been revolutionized by recombinant DNA technologies. These technologies enable the investigation of drug metabolism and disposition, as well as the study of posttranscriptional regulation of ADME genes.

DRUG METABOLISM AND DISPOSITION (2023)

Article Pharmacology & Pharmacy

Pharmacokinetic Feasibility of Stability-Enhanced Solid-State (SESS) Tenofovir Disoproxil Free Base Crystal

Byoung Hoon You, Mingoo Bae, Seung Yon Han, Jieun Jung, Kiwon Jung, Young Hee Choi

Summary: The pharmacokinetic feasibility of the stability-enhanced SESS-TD crystal was evaluated and found to be comparable to TDF, with no changes observed even after 12 months of storage. This suggests that the SESS-TD crystal may have enough pharmacokinetic feasibility to replace TDF.

PHARMACEUTICS (2023)

Article Pharmacology & Pharmacy

Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer

Yixin Chen, Mei-Juan Tu, Fangwei Han, Zhenzhen Liu, Neelu Batra, Primo N. Lara, Hong -Wu Chen, Huichang Bi, Ai -Ming Yu

Summary: The research found that miR-22-3p, miR-9-5p, and miR-218-5p are antiproliferative miRNAs targeting non-small cell lung cancer (NSCLC) cells, and they inhibit folate metabolism and alter amino acid metabolism in NSCLC cells. In addition, the inhibition of glucose uptake by miR-22-3p and the reduction of serine biosynthesis from glucose by miR-9-5p and -218-5p were also confirmed. Recombinant miR-22-3p was more effective than miR-9-5p and -218-5p in inhibiting NSCLC cell respiration, glycolysis, and colony formation, without causing any toxicity.

ACTA PHARMACEUTICA SINICA B (2023)

Article Pharmacology & Pharmacy

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice

Seo-Yeon Kim, Byung Hoon You, Mingoo Bae, Seung Yon Han, Kiwon Jung, Young Hee Choi

Summary: This study aimed to characterize the pharmacokinetic profiles of co-amorphous dispersions of Mirabegron (MBR) in rats and mice. The results showed that these co-amorphous dispersions can improve the relative bioavailability and area under the curve of MBR.

PHARMACEUTICS (2023)

Article Biochemistry & Molecular Biology

No Interference of H9 Extract on Trastuzumab Pharmacokinetics in Their Combinations

Seung Yon Han, Jeong-Eun Yu, Byoung Hoon You, Seo-Yeon Kim, Mingoo Bae, Hee-Sung Chae, Young-Won Chin, Soo-Hwa Hong, Ju-Hee Lee, Seung Hyun Jung, Young Hee Choi

Summary: In a mouse model, the combination of trastuzumab and H9 extract for breast cancer treatment showed no changes in trastuzumab pharmacokinetics, indicating that H9 does not affect the exposure of trastuzumab.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

暂无数据